In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Atyr Pharma Inc (NASDAQ: LIFE) closed at $1.59 down -1.24% from its previous closing price of $1.61. In other words, the price has decreased by -$1.24 from its previous closing price. On the day, 0.54 million shares were traded. LIFE stock price reached its highest trading level at $1.64 during the session, while it also had its lowest trading level at $1.58.
Ratios:
For a deeper understanding of Atyr Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.27 and its Current Ratio is at 6.27. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On October 12, 2021, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $22.
On September 21, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $19.Piper Sandler initiated its Overweight rating on September 21, 2021, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 06 ’24 when Broadfoot Jill Marie sold 1,590 shares for $1.69 per share. The transaction valued at 2,687 led to the insider holds 20,821 shares of the business.
Shukla Sanjay bought 12,000 shares of LIFE for $14,136 on Dec 12 ’23. The President and CEO now owns 106,173 shares after completing the transaction at $1.18 per share. On Dec 11 ’23, another insider, Shukla Sanjay, who serves as the President and CEO of the company, bought 3,000 shares for $1.17 each. As a result, the insider paid 3,510 and bolstered with 94,173 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LIFE now has a Market Capitalization of 108025872 and an Enterprise Value of 24463538. For the stock, the TTM Price-to-Sale (P/S) ratio is 307.78 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at 69.302 whereas that against EBITDA is -0.45.
Stock Price History:
Over the past 52 weeks, LIFE has reached a high of $2.70, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is -13.66%, while the 200-Day Moving Average is calculated to be -2.86%.
Shares Statistics:
For the past three months, LIFE has traded an average of 553.40K shares per day and 387370 over the past ten days. A total of 67.75M shares are outstanding, with a floating share count of 65.67M. Insiders hold about 3.07% of the company’s shares, while institutions hold 60.54% stake in the company. Shares short for LIFE as of 1711584000 were 436889 with a Short Ratio of 0.79, compared to 1709164800 on 108228. Therefore, it implies a Short% of Shares Outstanding of 436889 and a Short% of Float of 0.91.
Earnings Estimates
The stock of Atyr Pharma Inc (LIFE) is currently drawing attention from Anavex Life Sciences Corp. analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $1.41, with high estimates of $87.24 and low estimates of $63.23.
Analysts are recommending an EPS of between $Healthcare and $Financial Services for the fiscal current year, implying an average EPS of $Healthcare.
